<i>MYD88</i>, <i>CD79B</i>, and <i>CARD11</i> gene mutations in CD5‐positive diffuse large B‐cell lymphoma

Abstract

The incidence of MYD88 and CD79B mutations in patients with CD5⁺ DLBCL is lower than that in patients with DLBCL-SS, suggesting that CD5⁺ DLBCL is not the same disease as DLBCL-SS in terms of gene mutation status. CARD11 mutations are rare in patients with CD5⁺ DLBCL. Cancer 2017;123:1166-1173. © 2016 American Cancer Society.